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Drug resistance is a serious public health problem that threatens to thwart our 
ability to treat many infectious diseases [1-4]. Repeatedly, the introduction of new 
drugs has been followed by the evolution of resistance [5-12]. In principle there are 
two ways to address this problem – (i) enhancing drug development, and (ii) slowing 
drug resistance. We present data and a modeling approach based on queueing 
theory that explores how interventions aimed at these two facets affect the ability of 
the entire drug supply system to provide service. Analytical and simulation-based 
results show that, all else equal, slowing the evolution of drug resistance is more 
effective at ensuring an adequate supply of effective drugs than is enhancing the 
rate at which new drugs are developed. This lends support to the idea that evolution 
management is not only a significant component of the solution to the problem of 
drug resistance, but may in fact be the most important component. 
 
 In principle, the evolution of resistance to any particular drug is not problematic 
provided that an alternative drug is available. What matters is therefore the rate at which 
drug resistance evolves relative to the rate at which new drugs are brought to market. 
Consequently there are two ways to ensure the availability of effective drugs: (i) by 
increasing the rate of drug discovery, or (ii) by increasing the time it takes for resistance 
to evolve through better resistance management.  
 Approaches for increasing the rate of drug discovery are probably familiar, and 
include research devoted to developing screening technology for new compounds as well 
as developing new classes of antimicrobial agents. Approaches for slowing the evolution 
of resistance are perhaps less familiar, but include research into new strategies for 
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reducing the inappropriate use of antimicrobials, determining when and where existing 
drugs should be used in combination versus as sequential monotherapies, as well as 
determining the optimal dose and timing of deployment for these existing drugs [1, 13-
16]. Although precise estimates are difficult to come by, it would appear that the research 
effort devoted to drug discovery currently far exceeds that devoted to resistance 
management [1]. 
 Is this current disparity in the effort devoted to drug discovery versus resistance 
management an effective use of resources? To answer this question we need to determine 
the benefits, in terms of ensuring effective drug availability, of increasing the rate of drug 
discovery versus slowing the rate of evolution through better resistance management. At 
one level the answer to this question is obvious. If there is an upper limit to the number of 
drugs that can be developed for a particular disease, then at some point drug development 
will become effectively impossible. This would leave slowing evolution as the only 
option. But what if we are not yet facing this limitation on drug development? Here we 
show that even when there is no limit on the development of new drugs, slowing 
evolution is still inherently more effective. This thereby calls into question the current 
emphasis on the drug discovery side of the issue, and suggests that more emphasis ought 
to be given to evolution management.  
 Historical data for the development of new antimalarial and antibiotic drugs, as 
well as the evolution of resistance to these, is presented in Figure 1. The processes 
underlying these data are complex, with both geographical and temporal variation in the 
drugs that are used to treat specific infectious diseases. We construct and analyze a 
simplified model of these processes that abstracts only the essential features. The results 
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we present are generic (i.e., not specific to any particular drugs or diseases) but we 
illustrate them with specific examples whose parameter values are taken from data on 
malaria [6-12].  
 We define a “drug” as any whole treatment strategy, which might consist of one 
or multiple active ingredients. The “drug portfolio” is the collection of existing drugs that 
are effective against a specific type of infection. For simplicity we assume that a single 
drug is used at any given time, and its use is continued until resistance to this drug has 
appeared and reached some threshold frequency (e.g., 10% see [13]). The time it takes for 
this to occur is referred to as the ‘time to evolve resistance’, or equivalently the ‘drug 
lifespan’. It is denoted by the random variable L. At this point the use of the drug is 
effectively discontinued and another drug from the drug portfolio, if available, is then 
brought into use. During this process, new drugs are also in various stages of 
development and are occasionally brought into the drug portfolio. Although this is clearly 
a simplified description of reality, relaxing some of these assumptions (including 
allowing for multiple drugs to be used simultaneously) does not alter the important 
qualitative insights provided by our analysis (see Appendix). 
 The overall dynamics of the modeled drug supply system are shown 
schematically in Figure 2. Drug arrival into the drug portfolio, and the evolution of 
resistance both occur stochastically, resulting in periods of time for which effective 
treatment is available (i.e., when there is at least one effective drug in the drug portfolio), 
separated by periods when there is no effective treatment. We refer to the length of time 
during which effective treatment is available as the “time to failure” (denoted by T). 
These periods are separated by time intervals during which no effective treatment is 
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available (Figure 2). For example, the appearance of pan-resistant Klebsiella pneumoniae 
and multidrug resistant Tuberculosis suggest that we might well have exceeded the time 
to failure for these diseases, and be heading into a period in which no effective treatment 
is immediately available.  
 We can view the expected time to failure as the product of the expected number 
of drugs used before failure occurs, and the expected lifespan of each of these drugs. We 
will also be interested in the long-run fraction of time that effective treatment is available, 
and refer to this as the “drug availability”. The model is completely specified by the 
process of drug arrivals and the process of resistance evolution.  
 Recent analysis of a large data set for pharmaceutical production from companies 
during the period 1950-2008 has shown that the annual output of new drugs is Poisson 
distributed with a constant rate parameter [17]. This implies that the time between new 
drug arrivals is exponentially distributed. Consequently we define the random variable D 
to be the time between drug arrivals into the drug portfolio, and assume that D is 
exponentially distributed with rate parameter, 
! 
" . The expected time between drug 
arrivals is therefore 
! 
E[D] =1/" .  
 The time to evolve resistance (i.e., the drug lifespan, L) represents the time 
between when a drug is first used and when resistance to the drug reaches a threshold 
frequency. We assume that this lifespan is determined by the evolution of resistance, and 
therefore different evolution management strategies will result in different drug lifespans.  
Little is currently known about the distribution of L but we can make some progress by 
examining the data from Figure 1. Analyses suggest that, for some diseases at least (e.g., 
malaria), L is also approximately exponentially distributed (see Appendix). There are 
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many caveats associated with this conclusion, however, and therefore we consider two 
scenarios. First, we suppose that L is exponentially distributed with rate parameter 
! 
". The 
expected drug lifespan is therefore 
! 
E[L] =1/" . Second, we consider a case where the 
distribution of L is left arbitrary.  
 We begin the analysis by assuming that the average time between drug arrivals is 
larger than the average drug lifespan (i.e., E[D]>E[L]). This assumption is relaxed when 
we consider a variable rate of drug development. This implies that, with probability 1, 
there will be periods of time when drugs are available as well as periods of time when 
they are not (Figure 2).  
 Two interventions are explored: (i) increasing the expected drug lifespan 
! 
E[L] 
through better evolution management, or (ii) decreasing the expected time between drug 
arrivals 
! 
E[D] through enhanced drug discovery. In the additive case we consider 
increasing 
! 
E[L] by an additive amount or decreasing 
! 
E[D] by the same amount. In the 
multiplicative case we consider increasing 
! 
E[L] by a factor or decreasing 
! 
E[D] by the 
same factor. For completeness we explore both additive and multiplicative changes in 
each. We focus on two main system performance measures: the time to failure, T, which 
is a random variable, and the drug availability, ! (Figure 2). 
 When the distribution of the time to evolution, L, is exponential an explicit 
equation can be derived for the probability density of the time to failure, T. We obtain 
  
! 
fT (t) =
"
#
e$(#+" )t I1(2 #"t)
t   (1) 
where 
! 
I1(x)  is a modified Bessel function of the first kind (see Appendix). Likewise, 
drug availability is given by  
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! 
" =
#
$
.  (2) 
 Increasing the mean time to evolve resistance (i.e., increasing 
! 
E[L] =1/") or 
decreasing the mean time between drug arrivals (i.e., decreasing 
! 
E[D] =1/" ) both shift 
probability mass in equation (1) from low to high values of T. However, changes in the 
mean time to evolve resistance do so to a greater extent (Figure 3a). This is true 
regardless of whether the changes are additive or multiplicative (see Appendix). 
Likewise, drug availability, 
! 
" , is also increased more through an additive change in the 
mean time to evolve resistance, whereas both interventions have identical effects on 
! 
"  
when the changes are multiplicative (see Appendix).  
 When the distribution of time to evolve resistance is left arbitrary we can obtain 
an equation for an integral transform of the distribution of time to failure, from which we 
can calculate any of its moments (see Appendix). We focus here on the first moment (i.e., 
expected time to failure), which is 
 
! 
E[T] = E[L]1" E[L]/E[D] .  (3) 
The expression for drug availability in this case is identical to equation (2) (see 
Appendix). Again we can see that the expected time to failure, 
! 
E[T], increases more with 
a change in E[L] than it does with a change in E[D] (Figure 3b). And again this is true 
regardless of whether the changes are additive or multiplicative. The conclusions about 
drug availability are identical to the case where the distribution of time to evolution is 
exponential.  
 We also explored the case where the rate of drug development !  varies as an 
inverse function of the drug portfolio size (see Appendix). We studied this situation to 
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better understand the consequences of having drug development respond to drug demand. 
It also allows us to examine a case where the mean time between drug arrivals is shorter 
than the mean drug lifespan (i.e., E[D]<E[L]). Again, the results show that slowing 
evolution increases the expected time to failure and drug availability more than 
decreasing the time between drug arrivals (see Appendix).   
 
Discussion: 
 Our results illustrate that slowing the evolution of drug resistance has a greater 
effect on the performance of the drug supply system than does speeding up drug 
development. What is the underlying mechanism behind this result?  
 Both types of interventions increase the chance of developing new drugs before 
the system as a whole fails. Decreasing the time between drug arrivals does so because, 
on average, more drugs will arrive in a given period of time. Increasing the time to evolve 
resistance does so because it extends the window of opportunity for a new drug to be 
brought to market before failure occurs. In fact, when the changes for each intervention 
are multiplicative it can be shown that, on average, the same number of drugs will arrive 
and be used before failure occurs in both cases. The difference lies in how the 
interventions affect the lifespan of each drug. Recall that we can express the mean time to 
failure, E[T], as the product of the expected number of drugs that are used before failure 
and the expected lifespan of each drug. Mathematically,  
 
! 
E[T] = E[N] " E[L]   (4) 
where N is the number of drug used before system failure. As already described, 
multiplicative changes in both interventions have identical effects on E[N]. But changes 
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in the time to evolve resistance also affect E[L] whereas changes in drug development do 
not. As a result, increasing the expected time to evolve resistance has a compounding 
effect that is absent when changing the drug development time. Moreover, this effect is 
even greater when we consider additive changes in each intervention because changing 
the time to evolve resistance increases E[N] more than does changing the time for drug 
development.  
 Drug availability is the proportion of time for which there is effective treatment. 
Hence, even though there is a greater increase in time to failure when evolution is 
slowed, it is important to consider how enhancing the rate of drug arrivals reduces the 
fraction of time for which there is no effective treatment. In fact, as a result of a 
multiplicative change, the increase in time to failure from slowing evolution of resistance 
is equivalent to the increase in drug availability from speeding up drug development. 
However, if the change is additive, the added benefit to time to failure from slowing 
evolution exceeds the effect that decreasing time between drug arrivals has on drug 
availability, causing drug availability to increase more when evolution of resistance is 
slowed. 
 Our simplified model of the drug supply system assumes that, when available, 
drugs are used one at a time. However, the data in Figure 1 suggests that multiple drugs 
are often used simultaneously at the population level (although perhaps in different 
geographic regions [18, 19]]. Modeling the simultaneous use of multiple drugs is difficult 
because one needs to specify how the rate of resistance evolution to each drug is affected 
by the number of drugs in use (something for which virtually no data are available). 
Under some assumptions, however, allowing for simultaneous multiple drug use results 
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in a model that is formally identical to the model presented here (see Appendix). This 
shows that, under some conditions, all of the insights obtained in our simplified model 
carry over to this more complex situation. It also strongly suggests that, even for other 
simultaneous drug use scenarios, where an exact correspondence with the simple model 
no longer holds, the important processes elucidated here will continue to operate. Other, 
additional, processes might then occur as well, however, and this is therefore an 
important area for future research. 
 Our analysis does not consider how investments can be delivered to the system. 
Additive and multiplicative changes were used to determine the importance of speeding 
up drug arrivals relative to slowing evolution of drug resistance, which implies that 
changing either component in the same manner requires the same amount of resources or 
effort. However, it might be less costly or easier to change drug lifespan than to change 
drug development or vice versa. Further research in this area might consider assessing 
strategies using empirically supported cost functions for investments [4, 20-22].  
 Even though we provide evidence that slowing evolution of drug resistance is 
more beneficial to the effective management of resistance than speeding up drug 
development, we stress that this in no way negates the importance of pharmaceutical 
innovation and drug discovery. Indeed, the two approaches to resistance management 
need not always be traded off against one another. For example, slowing the evolution of 
drug resistance is, in many ways, fundamentally linked to drug development. Investment 
and advancement in drug development might lead to smarter drugs with enhanced 
efficacy and greater longevity. Thus our intention is not to suggest that there is, by 
necessity, an antagonism between the two approaches. The results do demonstrate, 
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however, that a greater emphasis on evolution management might yield promising results 
for this pressing problem.  
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Figures and Figure Legends: 
 
Figure 1. Drug supply timeline for antimalarials and anitbiotics. This gives the time of drug introduction and the subsequent evolution 
of resistance (6-12). We show the observed periods of time that effective treatment is available (green bars) separated by periods 
during which there is a risk of ineffective treatment (dashed red-lines) as a result of resistance. The color fading is meant to show that 
first observation of resistance does not absolutely equate with complete loss of treatment efficacy. 
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Effective treatment 
available  
No effective 
treatment 
Time to failure (T) 
Total time that there is effective treatment  
Drug availability (!) 
Total time effective 
treatment is unavailable 
Time course 
 
Figure 2. Illustration of drug supply. A schematic timeline defining the time to failure, T, and drug availability, 
! 
" . ‘Effective 
treatment available’ means that there is at least one effective drug in the portfolio. 
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Figure 3. Effects on time to failure from enhancing drug development and slowing evolution. (A) The effect on the time to failure 
density
! 
fT (t)  when the average time between drug arrivals is reduced by 2 years (orange line) and the average time to evolve 
resistance is extended by 2 years (blue line) compared to baseline conditions (black line; E[L] = 5 years, E[D] = 8.3 years). (B) The 
change in expected time to failure (E[T]) resulting from additive perturbations in E[L] (blue line) and E[D] (orange line) plotted for 
varying current drug availability (!) . 
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1 – Data 
 
Data were collected from various sources to create a timeline of drug supply for 
antimalarials and antibiotics (Table A1). The data consist of the date of introduction, and 
the date of first recorded resistance. When there existed multiple estimates for the same 
drug from a single source, we report the earliest date that the drug was introduced and the 
earliest date that resistance was first observed (this occurred when there was region-
specific data on drug introduction or resistance). While it is reported that resistance has 
developed to every antimalarial (with the possible exception of artemisinin therapies [3]), 
we excluded data on Lapdap, Amodiaquine, and Primaquine because the determination of 
drug resistance for these antimalarials was inconclusive (e.g., due to a lack of evidence or 
because of confounding factors in treatment failure such as cross resistance, side-effects, 
compliance and drug withdrawal [23-25]).  
 
We also used the available antimalarial data to give an example parameterization of the 
model. We stress, however, that this is intended merely as an illustrative case. All of the 
results reported in the main text are general, and independent of the disease in question as 
well as the specific parameter values used. We nevertheless chose to include an example 
parameterization based on data because it helps to clarify the relevance of the general 
results and to make them more concrete.  
 
Coming up with a suitable parameterization from the data is difficult because our 
simplified model lacks some of the features of the real data. Specifically, in the data 
many drugs have overlapping lifespans (elapsed time from date of drug introduction to 
date of observation of resistance). This suggests that more than one drug is used at a time 
during these periods. Our simple model assumes that one drug is used at a time (although 
Section 4 generalizes these results) and therefore we need to extract suitable estimates 
from the data under this assumption. For example, we cannot use the observed drug 
lifespans since the sum of individual drug lifespans would be greater than the observed 
time to failure, misrepresenting the current state of drug supply. As a result we employed 
two different approaches (see below) to estimate the time to evolve resistance from the 
data. The distribution of time to evolve resistance is almost identical under both 
approaches, and resembles an exponential distribution with rate parameter! = 0.2 (see 
Figure A1). The distribution of time between drug arrivals also resembles an exponential 
distribution with rate parameter ! = 0.12, supporting an assumption based on results from 
[17] (see Figure A1).   
 
Approach 1: Dividing overlapping periods by the number of drugs 
 
We can estimate the time to resistance of individual drugs by dividing overlapping 
periods by the number of drugs and summing the times that a particular drug was used. 
Section 4 describes how this approach can be used to generalize the one-drug-at-a-time 
model to a multiple drug scenario. In effect, this gives an estimate of the time to evolve 
resistance for each drug in the absence of any other drug.  
 
Approach 2: Time to evolve resistance from earliest drug arrival to first drug failure 
 
Alternatively, we can consider time to evolve resistance as the time from the earliest drug 
arrival to the time that resistance is first observed to any drug in an overlapping period. 
Using this approach, estimates of time to resistance are not necessarily for a specific 
drug, but instead reflect the time to resistance for a group of drugs (and the factors 
experienced by these drugs) that are in use during an overlapping period. 
 
Simulating the current and future state of antimalarial supply 
 
Antimalarial drug supply was simulated using the parameter estimates from the 
antimalarial data as described above. Figure A2 shows how periods of time to failure and 
drug availability observed from 1930-2012 in the antimalarial data agree with a 
characteristic simulation of the current state of drug supply. We can also envision what 
might happen to antimalarial supply in the future if we slowed resistance or enhanced 
drug development. In this case, we chose to compare an increase of 2 years in the mean 
time to evolve resistance with a decrease of 2 years in the mean time between drug 
arrivals. Figure A3 shows that increasing the mean time to evolve resistance results in 
significantly longer periods of time to failure, which also means that drugs will be 
available for a longer fraction of time over the next 200 years. 
 
Again we stress, however, that these simulation results are merely meant to be an 
illustrative example. The findings from the model are independent of the details of this 
simulation, and apply for any distribution of time to resistance, regardless of its shape or 
parameter values. The model also allows for the use of any (consistent) measure of 
resistance or drug failure since time to resistance is treated as a random process. In this 
example, the data report the first observation of resistance but we might wish to measure 
drug lifespan as the time until resistance is observed at some threshold frequency instead.  
 
 
2 – Analysis 
 
All models presented in the text are analogous to models from queueing theory. There are 
abundant results available for analyzing their behavior [26]. In what follows we make use 
of results found in [26].  
 
Exponentially Distributed Time to Evolve Resistance 
 
When the time to evolve resistance is exponentially distributed, the drug supply model is 
analogous to an M/M/1 queue [26]. Using 
! 
fT (t) to denote the probability density of the 
time to failure, and 
! 
˜ f T (z)  for its Laplace-Stieltjes transform (LST), standard results [26] 
demonstrate that 
 
! 
˜ f T (z) =
" + #+ z $ (" + #+ z)2 $ 4#"
2"  (Equation 1) 
 
where
! 
E[D] =1/"  and 
! 
E[L] =1/"  (Equation 1 is also derived below in the case of an 
arbitrary distribution for the time to evolve resistance).  
Inverting the transform gives the density [26] 
 
! 
fT (t) =
"
#
e$(#+" )t I1(2 #"t)
t  (Equation 2) 
 
where 
! 
I1(x)  is a modified Bessel function of the first kind with order 1. Specifically, 
! 
I1(x)  can be defined by the integral formula 
 
! 
I1(x) =
1
"
ex cos# cos#0
"
$ d# . (Equation 3) 
 
Drug availability, 
! 
" , is the long run proportion of time an effective drug is available. In 
the context of queueing theory this is referred to as the “load” or “traffic intensity”. 
Standard results [26] show that  
 
! 
" = E[L]/E[D]. (Equation 4) 
 
Equation 4 can be understood by recognizing that drug availability is the long-term time 
spent with at least one drug (which is, on average, E[T ]) divided by the length of the 
cycle (which is, on average, E[T ]+E[D] ). In other words, the ratio 
 
! 
E[T]
E[T]+ E[D] .  
 
Using Equation 2 we can calculate 
! 
E[T] = E[L]/(1" E[L]/E[D]) . Substituting this into 
the above ratio then gives Equation 4.
 
 
We can now determine the effect of each intervention on Equation 2 and Equation 4. The 
density (Equation 2) is a decreasing function of t and changes in 
! 
E[D] =1/"  or 
! 
E[L] =1/"  affect the density differently. For example,  
 
! 
lim
t" 0
fT (t) =
1
E[L] , 
 
shows that increasing the expected time to evolve resistance (either additively or 
multiplicatively) decrease the probability density at t = 0  whereas decreasing the 
expected time between drug arrivals has no effect at this point. Consequently, given that 
the density function is continuous, interventions that target evolution will shift more 
probability density from near zero to larger values of T than will interventions that target 
drug development. 
 
For the drug availability, Equation 4, we consider additive and multiplicative changes in 
turn. An additive change of size x will either add x to the mean time to evolve resistance 
or subtract x from the mean time between drug arrivals. A multiplicative change of size 
y>1 will either multiply the mean time to evolve resistance by y or divide the mean time 
between drug arrivals by y.   
 
For additive changes of size x the inequality  
 
! 
E[L]+ x
E[D] >
E[L]
E[D] " x  
 
holds for all x that satisfy the assumption that 
! 
"  is less than 1. Alternatively, 
multiplicative changes result in equal benefits to drug availability as  
 
! 
E[L] " y
E[D] =
E[L]
E[D]/ y . 
 
Therefore, when evolution of drug resistance is slowed, effective treatment will be 
available for a fraction of time greater than or equal to the effect from enhancing drug 
development. 
 
Arbitrary Distribution for the Time to Evolve Resistance 
 
When time to evolve resistance has an arbitrary distribution, the drug supply model is 
analogous to an M/G/1 queue [26]. We can derive an equation for the Laplace-Stieltjes 
transform (LST) of the time to failure distribution as follows. 
 
Any time to failure period begins with the arrival of a new drug into the portfolio. While 
this drug is in use, additional new drugs might be added to the portfolio. Suppose, for 
example, there are K additional drugs added during the time that the first drug is being 
used (K is a random variable). Each of these additional drugs will eventually be used, and 
each will, themselves, spawn a time to failure period that has the same distribution as that 
of the first drug. In this way we can write  
 
  
! 
T = L +T1 +!+TK  
 
where L is the time to evolve resistance for the first drug, and the Ti ’s are the time to 
failure periods for the additional K drugs that arrive before the first drug is abandoned. 
Using 
! 
fL (t) and 
! 
fT (t) to denote the probability densities for the time to evolve resistance 
and time to failure respectively, the LST of fT (t)  is 
! 
˜ f T (z) = E[e"zT ]. Conditioning on the 
lifespan of the first drug we obtain 
 
! 
˜ f T (z) = fL (t)E[e"zT | L = t]dt0
#
$ , 
 
and further conditioning on the number of new drug arrivals, K, during this time gives 
 
  
! 
˜ f T (z) = fL (t) E[e"z(L +T1 +!+TK ) | L = t,K = k]P(K = k | L = t)k =0
#
$( )dt0#%
= fL (t)e"zt E[e"z(T1 +!+Tk )]P(K = k | L = t)k =0
#
$( )dt0#%
= fL (t)e"zt E[e"z(T1 +!+Tk )]
(&t)k e"&t
k!k =0
#
$
' 
( 
) 
* 
+ 
, dt0
#
%
 
 
where the final equality makes use of the fact that K is Poisson distributed. Now, using 
the fact that the Ti ’s are iid, we obtain 
 
! 
˜ f T (z) = fL (t)e"zt E[e"zT ]k
(#t)k e"#t
k!k =0
$
%
& 
' 
( 
) 
* 
+ dt0
$
,
= fL (t)e"zt ˜ f T (z)k
(#t)k e"#t
k!k =0
$
%
& 
' 
( 
) 
* 
+ dt0
$
, .
 
 
Finally, noting that 
! 
zk ("t)
k e#"t
k!k=0
$
% = e(z#1)"t , this last expression simplifies to 
 
! 
˜ f T (z) = fL (t)e"zte
˜ f T (z )"1( )#tdt0
$
%
= fL (t)e" z+#"#
˜ f T (z)( )tdt0
$
%
 
 
or 
 
! 
˜ f T (z) = ˜ f L z +" #"˜ f T (z)( ) (Equation 5) 
 
Equation 5 is Takács functional equation relating the LST of the distribution of time to 
failure, T, to the LST of the distribution of time to evolve resistance, L.  
 
We can now calculate any moment of interest for the distribution of the time to failure, in 
terms of the moments of the distribution of time to evolve resistance. In particular, 
! 
E[T] = " ˜ f T '(0), and therefore 
 
! 
E[T] = E[L]1" E[L]/E[D] . (Equation 6) 
 
Notice that this is identical to the expression for E[T] obtained in the case of 
exponentially distributed time to evolve resistance, and therefore Equation 4 for drug 
availability remains valid even when the time to evolve resistance has an arbitrary 
distribution. 
 
Incidentally, we can also derive Equation 1 from Equation 5 by using the fact that, when 
L is exponentially distributed with parameter 
! 
", the LST of L is !fL (z) = ! / (! + z) . 
Substituting this into Equation 5 gives 
 
! 
˜ f T (z) =
"
"+ z +# $#˜ f T (z)
. 
 
Solving this quadratic equation for 
! 
˜ f T (z) gives Equation 1. 
 
When the distribution of L is arbitrary, we can consider the effect that additive and 
multiplicative changes have on any moment of the time to failure distribution. For the 
purposes of this analysis, we have chosen to focus on the first moment, the expected time 
to failure, E[T] (Equation 6). The expected time to failure can be broken up into two 
parts: the average number of drugs used before failure, 
! 
E[N] = 1" E[L]/E[D]( )"1and the 
average lifespan of each drug, E[L], such that 
! 
E[T] = E[N] " E[L]. The likelihood that 
another drug arrives before failure will increase as a result of slowing the time to evolve 
resistance or decreasing the time between drug arrivals. An additive change of size x 
increases the average number of drugs used before failure and, in particular, the 
inequality 
 
! 
1" E[L]+ xE[D]
# 
$ 
% 
& 
' 
( 
"1
> 1" E[L]E[D] " x
# 
$ 
% 
& 
' 
( 
"1
  
 
holds for all x that satisfy the assumption that 
! 
"  is less than 1. Alternatively, there is an 
equivalent increase in the average number of drugs used before failure when evolution is 
slowed and drug development is enhanced multiplicatively since 
 
! 
1" E[L] # yE[D]
$ 
% 
& 
' 
( 
) 
"1
= 1" E[L]E[D]/ y
$ 
% 
& 
' 
( 
) 
"1
. 
 
This shows that increasing the mean time to evolve resistance will result in at least as 
many drugs used before failure as decreasing the mean time between drug arrivals. In 
addition, since increasing the mean time to evolve resistance also increases average drug 
lifespan, the total effect on average time to failure is that much greater when resistance is 
slowed than when drug development is enhanced. 
 
We also show how increasing the mean time to evolve resistance or decreasing the mean 
time between drug arrivals affects the whole time to failure distribution. The drug supply 
system was simulated for a constant rate of drug arrivals by randomly selecting the time 
between drug arrivals from an exponential distribution with rate ! . The time it takes to 
evolve resistance to a drug was randomly selected from a normal distribution with 
expected time to evolve drug resistance, E[L]= µ , and standard deviation ! . Figure A4 
shows that this entire distribution shifts more toward longer durations of time to failure 
when the evolution of drug resistance is slowed than when the rate of drug arrivals is 
sped up, thereby producing the larger change in expected value of T described above. 
 
 
3 – Variable Rate of Drug Development 
 
Model 
 
We will also consider a variable rate of drug arrivals so that drugs arrive at a normal rate, 
! 
"D, when there are lots of drugs in the drug portfolio and a fast rate, !F , when there are 
few effective drugs available. The normal rate of drug arrivals was varied to determine 
the effect of speeding up drug development. As before, these results were compared 
against the effect of slowing evolution of resistance. In these simulations, the proportion 
of time that drugs arrived at their respective rates was also considered. 
 
The available empirical evidence suggests that annual drug production has been constant 
for over 55 years, remaining unchanged in spite of increased investment [17]. Even so, by 
including a fast rate, the time between drug arrivals is not necessarily longer than the time 
it takes resistance to evolve, relaxing the E[D]>E[L] assumption of the previous model. 
Results from this simulations also show that slowing the evolution of resistance has a 
greater impact on time to failure and drug availability than does speeding up the normal 
rate of drug arrivals. 
 
Results 
 
Numerical results show that slowing the evolution of resistance benefits time to failure 
and drug availability more than speeding up the normal rate of drug arrivals (Table A2).  
Slowing evolution of drug resistance also decreased the proportion of time that drugs 
arrived according to a fast rate of development (Figure A5). This suggests that drug 
arrivals were occurring close to a maximum rate, so that any further increase in the 
normal rate of drug arrivals would have little effect on system performance. In contrast, 
when evolution was slowed, a normal rate of drug arrival was used for a greater 
proportion of time implying that the average rate of drug arrivals slowed down when E[L] 
increased. 
 
 
4 – Generalizing to Multiple Drugs 
  
Thus far, we have presented a model of drug supply that assumes one drug or drug 
therapy is used at a time. While this assumption is supported by current treatment 
guidelines and practice for malaria (wherein a single first line therapy is recommended 
for treatment and replaced when resistance emerges [13, 27]) in general, it is likely that 
more than one drug will be used to treat a disease when available. Note, by this we mean 
that individuals are still given a single drug, but different individuals might be given 
different drugs simultaneously. 
 
To begin it is helpful to first consider how simultaneous drug use affects the total time 
required to evolve drug resistance for a set of drugs, relative to that required if the drugs 
in this set were used one at a time (i.e., sequentially). There are three possibilities: (i) 
conservation of evolution, (ii) compression of evolution, and (iii) expansion of evolution. 
These are defined as follows.  
 
Suppose there are n drugs currently available. We say that there is conservation of 
evolution if the total time it takes for resistance to evolve to all n drugs when used 
simultaneously is the same as the time required for resistance to evolve to all n drugs 
when used sequentially. Alternatively, we say that there is compression of evolution if the 
time taken under simultaneous drug use is shorter, and expansion of evolution if it is 
longer. We will show that this provides a heuristic framework with which to examine 
multiple drug use. 
 
It can be shown, using results from work-conserving queueing theory [28], that a model 
with simultaneous drug use is formally equivalent to a one-drug-at-a-time model when 
there is conservation of evolution. We propose a mechanistic basis by which this occurs. 
Suppose that the rate of evolution for individual drugs depends on the number of drugs in 
use, n, such that the rate of evolution for each drug is slowed by a factor 1/n relative to 
the rate of resistance evolution if it were the only drug in use. Then it can be shown that 
the distribution of time to failure is unchanged from a one drug at a time model, as this is 
analogous to a work-conserving queue [28]. In a similar way, we can account for drugs 
used at different frequencies by assuming that the rate of evolution of resistance to each is 
slowed by a factor equal to its frequency of use.  
 
These ideas reveal that, under certain conditions (namely, conservation of evolution) the 
results of the simple model of the text are identical to those for a model that allows 
simultaneous multiple drug use. Therefore, increasing the mean time to evolve resistance 
is more effective than decreasing the mean time between drug arrivals in an evolution-
conserving scenario of multiple drug use. This also provides a natural point of departure 
for exploring cases in which evolution is not conservative.  
  
When multiple drug use results in compression of evolution, this means that there are 
interactions among drugs that result in a reduction of the time required to evolve 
resistance. This effect might arise from cross-resistance, wherein the mechanism of 
resistance to one drug also confers resistance to another drug, effectively reducing its 
lifespan. This means that it is more important to slow resistance than to enhance drug 
development, as simply using more drugs will reduce the lifespan of each drug.  
 
Alternatively, when multiple drug use results in the expansion of evolution, this means 
that there are interactions among drugs that bring about an increase in the time required 
for resistance evolution. In large part, it is precisely these interactions that have 
succeeded in the development of combination therapies as a single treatment for 
individuals. At the population level, drug mixing has been suggested as a way of spatially 
varying the drug environment so that it is more difficult for microbes to evolve resistance 
to any one drug [29].  
5 – Supplementary Tables 
 
Table A1. Data for antimalarials and antibiotics. The values indicate the time of drug 
introduction and first observation of drug resistance. The reference for each drug is 
provided; all data is from published sources. 
Drug Drug Type Introduced Resistance Source 
Chloroquine Antimalarial 1933.5 1957 (a) 
Sulfadoxine-pyrimethamine Antimalarial 1940 1953 (a) 
Proguanil Antimalarial 1948 1949 (b) 
Pyrimethamine Antimalarial 1951.5 1952.5 (c) 
Mefloquine Antimalarial 1977 1982 (d) 
Halofantrine Antimalarial 1988 1992 (b) 
Atovaquone Antimalarial 1996 1996 (d) 
Atovaquone-proguanil Antimalarial 1996.5 2001.5 (c) 
Artemisinin Antimalarial 2000 2009 (a) 
Sulfonamides Antibiotic 1930 1940.5 (e) 
Penicillin Antibiotic 1943 1946 (f) 
Streptomycin Antibiotic 1943 1959 (f) 
Chloramphenicol Antibiotic 1947 1959 (f) 
Tetracycline Antibiotic 1948 1953 (f) 
Erythromycin Antibiotic 1952 1988 (f) 
Vancomycin Antibiotic 1956 1988 (f) 
Methicillin Antibiotic 1960 1961 (f) 
Cephalosporins Antibiotic 1960.5 1969.5 (e) 
Ampicillin Antibiotic 1961 1973 (f) 
Gentamicin Antibiotic 1967 1970 (g) 
Oxyimino-beta-lactams Antibiotic 1981 1983 (g) 
Linezolid Antibiotic 1999.5 2003.5 (e) 
Daptomycin Antibiotic 2003.5 2005 (e) 
(a) Shetty P (2012) Malaria – the numbers game. Nature 484:A14-A15. 
(b) Thayer AM (2005) Fighting malaria. Chemical and Engineering News 83:69-82. 
(c) Hyde JE (2005) Drug-resistant malaria. Trends Parasit. 21:494-498. 
(d) Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR (2002) Epidemiology 
of drug-resistant malaria. Lancet Infect Dis 2:209-218. 
(e) Clatworthy AE, Pierson E, Hung DT (2007) Targeting virulence: a new paradigm for 
antimicrobial therapy. Nat Chem Biol 3:541-548. 
(f) Palumbi SR (2001) Humans as the world’s greatest evolutionary force. Science 
293:1786-1790. 
(g) Jacoby GA (2009) in Antimicrobial Drug Resistance, ed Mayers DL (Humana Press, 
New York), pp 3-7. 
 
Table A2. Performance measures for a variable rate of drug development. Results from 
simulations (n = 100) with a variable rate of drug arrivals over a time interval of 300 
years. The mean time between drug arrivals was 5 years (E[F] = 5) when there were less 
than 3 drugs in the system at the time of the last drug arrival. An additive change affects 
the mean time to evolve resistance or mean normal time between drug arrivals by 2 years, 
while a multiplicative change doubles the mean time to resistance or halves the mean 
normal time between drug arrivals. Average drug availability is the drug availability 
realized for each simulation averaged over all simulations. Average time to failure and 
down time is the average time to failure and down time for each simulation averaged over 
all simulations. Average proportion of time that drugs arrived from a particular rate is 
equal to the proportion of time the rate is used for each simulation averaged over all 
simulations. 
 
Initial 
conditions 
Additive 
change 
Multiplicative 
change 
(Mean time between drug arrivals, 
Mean time to evolve resistance) 10, 3 10, 5 8, 3 10, 6 5, 3 
Average drug availability 
 0.523 0.737 0.541 0.813 0.592 
Average time to failure (years) 
 6.227 18.629 6.444 29.652 7.764 
Average down time (years) 
 5.721 6.814 5.479 7.024 5.165 
Average proportion of time fast 
rate used 0.746 0.471 0.741 0.358 0.731 
 
6 – Supplementary Figures 
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Figure A1. Histograms of drug supply parameters from antimalarial data. (A) The 
distribution of time between drug arrivals (!  = 0.12, D = 8.3 years, !D = 7.7 years). The 
distribution of time to evolve resistance was estimated via two approaches: (B) by 
dividing overlapping regions by the number of drugs (!  = 0.2, L = 5 years, ! L = 5.2 
years) or (C) using the time from earliest drug arrival to first drug failure (!  = 0.2, L  = 5 
years, ! L = 4.6 years). Using the estimate of the rate parameter in each panel, the solid 
line is the exponential density plot and the open circles give the probability (%) within 
the interval defined by the width of each bar. The dashed line is the average value of the 
variable of interest. 
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Figure A2. The current state of antimalarial supply. This shows the time to failure (T; green bars) and drug availability (!)  
observed from data and from simulation using parameter estimates (E[L] = 5, E[D] = 8.3).  
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Figure A3. Characteristic realizations of future antimalarial supply. A simulation over the next 200 years when the mean time 
between drug arrivals is reduced by 2 years or the mean time to evolve resistance is increased by 2 years (compared to initial 
conditions: E[L] = 5, E[D] = 8.3). 
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Figure A4. Histograms of time to failure from simulation. (A) For initial conditions 
(E[D] = 10, E[L] = 3, ! L = 0.1), and after a multiplicative change is applied: (B) halving 
the mean time between drug arrivals (E[D] = 5, E[L] = 3, ! L = 0.1) or (C) doubling the 
mean time to evolve drug resistance (E[D] = 10, E[L] = 6, ! L = 0.1). The last bar in each 
histogram shows lengths of time to failure greater than or equal to 29 years and the 
dashed line indicates the average length of time to failure in each panel. 
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Figure A5. Characteristic simulations of a variable rate of drug development. The pattern 
of time to failure (green bars) and down time (red lines) along with the periods that a fast 
rate (orange bars) and normal rate (blue lines) of drug arrivals were used over a time 
interval for (A) initial conditions (E[D] = 10, E[F] = 5, E[L] = 3, ! L = 0.1), and after an 
additive change is applied: (B) subtracting 2 from the mean normal time between drug 
arrivals (E[D] = 8, E[F] = 5, E[L] = 3, ! L = 0.1) or (C) adding 2 to the mean time to 
evolve drug resistance (E[D] = 10, E[F] = 5, E[L] = 5, ! L = 0.1). The mean time between 
drug arrivals when there are less than 3 drugs in the drug portfolio is held constant at 5 
(E[F] = 5). Drug availability is shown at the bottom of each plot as the sum of time to 
failure (green area) relative to the sum of down time (red area) over the time interval. The 
proportion of time that drugs arrived from a fast rate (orange area) rate relative to a 
normal rate (blue area) is also shown. 
